A Case of Breast Cancer Achieving pCR after Pembrolizumab + Paclitaxel + Carboplatin Therapy Despite Developing irAE
-
- SHIMOYAMA Saki
- Department of Surgery, Toyohashi City Hospital
-
- FUJII Masahiro
- Department of Surgery, Toyohashi City Hospital
-
- FUKAYA Masahide
- Department of Surgery, Toyohashi City Hospital
-
- AOBA Taro
- Department of Surgery, Toyohashi City Hospital
-
- HATASA Misaki
- Department of Surgery, Toyohashi City Hospital
-
- HIRAMATSU Kazuhiro
- Department of Surgery, Toyohashi City Hospital
Bibliographic Information
- Other Title
-
- irAEによりpembrolizumab併用薬物療法を早期中止するもpCRを得た乳癌の1例
- irAE ニ ヨリ pembrolizumab ヘイヨウ ヤクブツ リョウホウ オ ソウキ チュウシ スル モ pCR オ エタ ニュウガン ノ 1レイ
Search this article
Description
<p>We report the case of a 77-year-old female patient whose main affliction upon presenting at our hospital was a tumor in the right breast. She was diagnosed with cT4bN0M0 Stage IIIB, triple-negative, cancer of the right breast. She was initiated on neoadjuvant therapy consisting of a pembrolizumab + paclitaxel + carboplatin regimen. During the 4th cycle of treatment, the patient complained of fever, fatigue, and exertional dyspnea. After blood tests and a contrast-enhanced computed tomography scan, she was diagnosed with a pulmonary embolism, drug-induced lung injury, and pituitary inflammation, suggesting an immune-related adverse event (irAE) caused by pembrolizumab. After the administration of an anticoagulant and a steroid pulse, the symptoms improved. The patient was discharged on the 17th day of hospitalization. The neoadjuvant therapy was discontinued, and two months after the onset of the irAE, a right breast total mastectomy and sentinel lymph node biopsy were performed. Pathological examination revealed no viable tumor cells.</p><p>Because pembrolizumab combination therapy is the standard care for triple negative breast cancer, irAEs should be considered. In this case, the neoadjuvant therapy was discontinued due to irAE, but pCR was nonetheless achieved. The treatment strategy should be determined based on the severity of the irAE and the therapeutic effect of the adjuvant therapy.</p>
Journal
-
- Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association)
-
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) 85 (2), 227-231, 2024
Japan Surgical Association
- Tweet
Keywords
Details 詳細情報について
-
- CRID
- 1390864324978290688
-
- NII Book ID
- AA11189709
-
- ISSN
- 18825133
- 13452843
-
- NDL BIB ID
- 033371908
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- NDL Search
- Crossref
-
- Abstract License Flag
- Disallowed